University of Pennsylvania and Novartis Form Alliance to Expand Use of Personalized T Cell Therapy for Cancer Patients. In addition to continued trials in chronic lymphocytic leukemia, Penn also has engineered T cell trials underway for other leukemias as well as lymphoma, mesothelioma, myeloma, and neuroblastoma.